Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.

Loxo Oncology's recent FDA filing for its TRK inhibitor larotrectinib in any advanced solid tumour with an NTRK fusion is another step forward for the new, purely molecular approach to cancer therapy.

Add Yahoo as a preferred source to see more of our stories on Google. About 29% of U.S. adults are religiously unaffiliated according to a Pew Research study, either identifying as an atheist, ...

Forbes contributors publish independent expert analyses and insights. Mark C. Perna is a generational expert who covers education & careers. This article is more than 4 years old. Valuing workers for ...